Stereotactic Radiosurgery · Spine
Primary & Benign Spinal Targets
Intradural benign tumors, primary bone tumors, vascular and benign-aggressive lesions — where focal radiation fits
Most spine SBRT treats metastases, but a heterogeneous group of primary and benign spinal targets also reaches the radiosurgical conversation — usually as an adjuvant, for residual or recurrent disease, or when surgery would be morbid. As in the cranial compartment, the organizing question is whether the lesion is benign-and-control-able, radioresistant-and-dose-hungry, or fundamentally a surgical problem. This page surveys those targets and where focal radiation does and does not belong.
Orientation
For benign intradural tumors (schwannoma, meningioma), surgery remains the primary treatment and SBRT is reserved for residual, recurrent, multiple (e.g., neurofibromatosis), or poor-surgical-candidate disease. For primary bone tumors, the chordoma/chondrosarcoma logic from the cranial compartment carries over — radioresistant tumors needing maximal resection and high-dose radiotherapy, often with particles. The cord constraint and the selection frameworks from the foundations and clinical pages apply throughout.
Benign Intradural Tumors
1.Spinal schwannoma, neurofibroma, and meningioma
Benign intradural-extramedullary tumors — schwannomas, neurofibromas, and meningiomas — are predominantly surgical, with resection offering both diagnosis and cure for most accessible lesions. Spine SBRT has a selective role: residual or recurrent tumor, surgically difficult locations, poor surgical candidates, and multiple lesions in the phakomatoses (NF1, NF2, schwannomatosis) where repeated open surgery is undesirable. Reported control of benign intradural tumors with focal radiation is high — on the order of ~90%+ local control at the marginal doses used cranially for the same histologies (single-fraction roughly 12–16 Gy, or a hypofractionated equivalent when the spinal cord is close) — but the evidence base is smaller and the default for a healthy patient with a resectable symptomatic tumor remains microsurgery. As always in the spine, the cord point-maximum constraint is what most often forces fractionation over a single session.
Primary Bone Tumors
2.Chordoma, chondrosarcoma, and benign-aggressive lesions
Primary spinal/sacral chordoma and chondrosarcoma follow the same principle as their clival counterparts: maximal safe resection (en-bloc where feasible) plus high-dose radiotherapy, with protons/particles frequently preferred for the dose escalation these radioresistant tumors demand (definitive doses on the order of 70–78 Gy(RBE) equivalent against cord-tolerance limits). Spine SBRT serves as a boost or for unresectable/recurrent disease, where a high biologically effective dose (e.g., high single-fraction or hypofractionated regimens) is needed because conventional doses underperform against chordoma. A separate group of benign-but-locally-aggressive lesions — giant cell tumor of bone, aneurysmal bone cyst, osteoblastoma — are primarily managed surgically (with systemic options such as denosumab for giant cell tumor), and radiation is used selectively given the benign nature and, in younger patients, late-effect concerns. Osteosarcoma and Ewing sarcoma of the spine are managed within sarcoma multidisciplinary protocols (chemotherapy, surgery, radiotherapy) rather than as standalone SBRT targets.
Vascular and Other Benign Lesions
3.Spinal vascular malformations and vertebral hemangioma
Spinal arteriovenous malformations and dural arteriovenous fistulae are treated by endovascular embolization and/or microsurgery; radiosurgery has only an investigational, highly selective role for inaccessible intramedullary AVMs and is not a standard option. Spinal hemangioblastoma (often VHL) parallels its cranial form — surgery for symptomatic/cystic lesions, with SBRT controlling small solid nodules in multifocal disease. Common benign vertebral hemangiomas are usually incidental and asymptomatic and rarely require treatment; the aggressive symptomatic variant is addressed with surgery, embolization, vertebroplasty, or conventional radiotherapy rather than ablative SBRT.
| Target | Primary treatment | Role of focal radiation |
|---|---|---|
| Schwannoma / neurofibroma | Microsurgery | SBRT for residual/recurrent, multiple (NF), poor candidates |
| Spinal meningioma | Microsurgery | SBRT selective (residual/recurrent, high-risk surgery) |
| Chordoma / chondrosarcoma | Maximal resection + high-dose RT (often protons) | SBRT as boost or for unresectable/recurrent |
| Giant cell tumor / ABC / osteoblastoma | Surgery (± denosumab for GCT) | Radiation selective; late-effect caution in young patients |
| Spinal AVM / dAVF | Embolization ± microsurgery | Radiosurgery investigational/highly selective |
| Hemangioblastoma | Surgery for symptomatic/cystic | SBRT for small solid nodules (VHL/multifocal) |
Key points
- Benign intradural tumors (schwannoma, neurofibroma, meningioma) are primarily surgical; SBRT is selective — residual/recurrent, multiple (NF), or poor surgical candidates.
- Spinal/sacral chordoma and chondrosarcoma need maximal resection + high-dose RT (often protons); SBRT is a boost/unresectable tool, not a standalone tight margin.
- Benign-aggressive bone lesions (GCT, ABC, osteoblastoma) are surgery-first (denosumab for GCT); radiation is selective with late-effect caution in the young.
- Spinal AVM/dAVF are embolization/microsurgery disease; radiosurgery is investigational and highly selective. Most vertebral hemangiomas need no treatment.
- Throughout, the cord constraint and NOMS/SINS/ESCC selection logic from the foundations and clinical pages still govern.
References
- Gerszten PC, Quader M, Novotny J Jr, Flickinger JC. Radiosurgery for benign tumors of the spine: clinical experience and current trends. Technol Cancer Res Treat. 2012;11(2):133–139. PubMed
- Taori S, Adida S, Kann MR, et al. Spine stereotactic radiosurgery provides long-term local control and overall survival for benign intradural tumors. Neurosurgery. 2024. PubMed
- Stacchiotti S, Sommer J; Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16(2):e71–e83. PubMed
- Sahgal A, Chang JH, Ma L, et al. Spinal cord dose tolerance to stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2021;110(1):124–136. PubMed
Educational survey for neurosurgery and radiation-oncology trainees; not a treatment directive. These less-common spinal indications are managed within multidisciplinary review; benign/primary spine references verified against PubMed during review.